ASH 2021 | Myeloma XI: early relapse exploratory analysis
Charlotte Pawlyn, BA, MB BChir, PhD, MRCP, from the Royal Marsden Hospital NHS Foundation Trust, London, UK, discusses an exploratory analysis of the Myeloma XI clinical trial (NCT01554852), which aimed to investigate early relapse. The Myeloma XI trial saw patients given a quadruplet induction combination treatment regimen (carfilzomib, lenalidomide, cyclophosphamide, dexamethasone) followed by autologous stem cell transplant and random assignment of lenalidomide maintenance. Dr Pawlyn mentions her interest in early relapse and shares insights on how observing genetic and potential phenotypic predispositions in patients may allow early relapse disease to be better predicted and monitored, resulting in better outcomes. This interview took place at the 63rd American Society of Hematology Annual Meeting and Exposition, Atlanta, 2021.
Disclosures
Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel support; Amgen: Honoraria; Celgene / BMS: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Oncopeptides: Other
